CUAMC
SRPT icon

China Universal Asset Management Company’s Sarepta Therapeutics SRPT Stock Holding History

China Universal Asset Management Company’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$721K Buy
40,102
+16,507
+70% +$312K 0.04% 234
2026
Q1 		$513K Buy
23,595
+6,520
+38% +$126K 0.04% 257
2025
Q4 		$367K Sell
17,075
-53
-0.3% -$1.12K 0.03% 283
2025
Q3 		$330K Sell
17,128
-2,611
-13% -$46.5K 0.03% 282
2025
Q2 		$338K Buy
19,739
+276
+1% +$11.8K 0.03% 277
2025
Q1 		$1.24M Sell
19,463
-791
-4% -$83.3K 0.12% 160
2024
Q4 		$2.46M Buy
20,254
+1,912
+10% +$234K 0.23% 90
2024
Q3 		$2.29M Buy
18,342
+7,237
+65% +$1M 0.25% 84
2024
Q2 		$1.75M Sell
11,105
-6,923
-38% -$889K 0.25% 75
2024
Q1 		$2.33M Buy
18,028
+7,204
+67% +$882K 0.3% 75
2023
Q4 		$1.04M Buy
10,824
+8,427
+352% +$808K 0.2% 106
2023
Q3 		$291K Buy
2,397
+1,176
+96% +$133K 0.08% 127
2023
Q2 		$140K Buy
1,221
+29
+2% +$3.74K 0.04% 143
2023
Q1 		$164K Buy
1,192
+300
+34% +$38.9K 0.06% 119
2022
Q4 		$116K Buy
892
+72
+9% +$8.34K 0.05% 118
2022
Q3 		$91K Buy
+820
New +$82.7K 0.04% 112

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

China Universal Asset Management Company's SRPT Position: Q2 2026 in Review

China Universal Asset Management Company increased its Sarepta Therapeutics (SRPT) stake by 70% in Q2 2026, buying an estimated $312K and bringing the position to 40,102 shares worth $721K. The position accounts for 0.04% of the portfolio, ranked #234.

China Universal Asset Management Company first reported a position in SRPT in Q3 2022 and has held it in 16 quarters since. The position peaked at $2.46M in Q4 2024. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • China Universal Asset Management Company held 40,102 shares of Sarepta Therapeutics worth $721K as of Q2 2026.
  • China Universal Asset Management Company bought 16,507 Sarepta Therapeutics shares in Q2 2026, an estimated $312K.
  • Sarepta Therapeutics made up 0.04% of China Universal Asset Management Company's portfolio in Q2 2026, its #234 holding.
  • China Universal Asset Management Company first reported a position in Sarepta Therapeutics in Q3 2022 and has held it in 16 quarters since.
  • China Universal Asset Management Company's Sarepta Therapeutics position peaked at $2.46M in Q4 2024.
  • 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on China Universal Asset Management Company's 13F filing for Q2 2026, filed 24 Jul 2026.